Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case for bladder botulinum toxin application.

Dae Kyung Kim1, Catherine A Thomas, Christopher Smith

  • 1Department of Urology, Eulji University School of Medicine, 1306 Dunsandong Seogu, Daejeon, Korea.

The Urologic Clinics of North America
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomechanical evaluation of humeral torsional strength following biceps tenodesis: A cadaveric study.

Clinical biomechanics (Bristol, Avon)·2026
Same author

What is the optimum incision for superficial temporal artery biopsy? An anatomical study using body donors.

Surgical and radiologic anatomy : SRA·2026
Same author

Thoracic Duct-to-Azygous Vein Lymphovenous Anastomosis for Lymphatic Decompression: Initial Experience and Early Outcomes.

Annals of thoracic surgery short reports·2026
Same author

Rat strain differences in bronchoalveolar lavage fluid and minimal association with histopathology findings.

Inhalation toxicology·2026
Same author

Optimization and External Validation of a Deep Learning Model for Segmentation and Quantification of Traumatic Brain Injury Lesions on Head Computed Tomography.

Journal of neurotrauma·2026
Same author

Tolerance and Tachyphylaxis to Medications for Attention-Deficit/Hyperactivity Disorder (ADHD): A Systematic Review of Empirical Studies.

CNS drugs·2026
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Botulinum toxin (BoNT) effectively treats neurogenic detrusor overactivity and is now being explored for idiopathic bladder overactivity. Further research is needed due to lack of regulatory approval for lower urinary tract use.

Area of Science:

  • Urology
  • Neurology
  • Pharmacology

Background:

  • Detrusor overactivity is a condition causing urinary urgency and frequency.
  • Neurogenic causes, such as spinal cord injury or multiple sclerosis, are common.
  • Idiopathic detrusor overactivity has no identifiable neurological cause.

Purpose of the Study:

  • To review the efficacy of botulinum toxin (BoNT) in treating neurogenic detrusor overactivity.
  • To establish BoNT as a potential therapeutic option for idiopathic bladder overactivity.
  • To highlight the current regulatory status and need for further research.

Main Methods:

  • Literature review of studies on botulinum toxin for detrusor overactivity.
  • Analysis of treatment outcomes in patients with neurogenic and idiopathic conditions.

Related Experiment Videos

  • Assessment of safety and efficacy data.

    • Main Results:

    • Botulinum toxin (BoNT) demonstrates effectiveness in suppressing detrusor overactivity in neurogenic cases.
    • Emerging evidence suggests BoNT may also benefit patients with idiopathic detrusor overactivity.
    • Current application in the lower urinary tract lacks regulatory approval.

    Conclusions:

    • Botulinum toxin is a viable treatment for neurogenic detrusor overactivity.
    • BoNT shows promise for treating idiopathic bladder overactivity.
    • Caution is advised due to the need for larger randomized clinical studies and regulatory clearance.